Several fixed-dose combination drugs marketed in the mid-20th century were later withdrawn due to safety concerns, changing regulatory standards, or abuse potential. Notable examples include: • Dexamyl – a combination of dextroamphetamine and amobarbital, used as a stimulant-sedative preparation, withdrawn in the early 1980s. • Tuinal – a combination of two barbiturates, amobarbital and secobarbital, prescribed as a sedative and hypnotic; it became notable both for medical use and recreational abuse. * Ethobral by Wyeth combined secobarbital,
butabarbital, and phenobarbital • Anox (Anox Diacels) – a triple barbiturate plus stimulant combination (phenobarbital, butabarbital, secobarbital, with methamphetamine and dextroamphetamine), reflecting the mid-century trend of “upper-lower” formulations. • Fenfluramine/phentermine (fen-phen) – an appetite suppressant combination withdrawn in 1997 after reports of cardiac valve toxicity. • Mandrax and Durophet – a combination of
methaqualone and diphenhydramine, widely used recreationally in South Africa until 1993. • Obetrol and Biphetamine –
mixed amphetamine salts used historically for obesity and attention disorders. •
Eskatrol – combined dextroamphetamine with prochlorperazine, historically prescribed for appetite suppression. •
Amfecloral (dextroamphetamine/
chloral hydrate) discontinued 1973 •
Obocell) combined 10 mg dextroamphetamine
tannate with 35 mg secobarbital These examples illustrate a period when pharmaceutical companies marketed combination drugs to address multiple therapeutic effects simultaneously, often combining stimulants and sedatives in the same formulation. Many such products were eventually withdrawn due to safety, abuse potential, or evolving regulatory standards. == Justification of medical use ==